Nancy Lin

Has grant

Associate Professor of Medicine

Dana-Farber Cancer Institute
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Open

ctDNA Guided Care in Patients with Metastatic Breast Cancer

Open Date: 2026-10-01

Close Date: 2028-09-30

Grant: Close

Improving Therapeutic Options for Patients with Breast Cancer and Central Nervous System Metastases

Open Date: 2023-10-01

Close Date: 2024-09-30

Grant: Close

Improving Therapeutic Options for Patients with Breast Cancer Brain Metastases

Open Date: 2022-10-01

Close Date: 2023-09-30

Articles (21)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Importance Brain metastases portend poor prognosis in patients with metastatic breast cancer (MBC). Designing treatment and prevention clinical trials requires knowledge of brain metastases incidence with each line of therapy. Objectives We assessed the prevalence and cumulative incidence of brain metastases in a large MBC patient cohort by subtype and line of therapy, and the impact of HER2-low expression on prevalence. Design, Setting and Outcomes We analyzed brain metastases prevalence in patients with MBC in a nationwide electronic health record-derived de-identified database. The primary outcome was first diagnosis of brain metastases. We estimated prevalence and incidence of brain metastases by MBC subtype, including HER2-low and therapy line. We used the cumulative incidence function to estimate brain metastases risk in patients without brain metastases at initiation of systemic therapy. All P-values are 2-sided, and a P-value ≤.05 indicates statistical significance. Results Among 18 075 patients with MBC, 1102 (6.1%) had at least 1 brain metastasis at first-line therapy initiation. For the remaining 16 973 patients, cumulative incidence of brain metastases at 60 months was 10% in patients with hormone receptor-positive (HR+)/HER2− disease, 23% for HR+/HER2+ disease, 34% for HR−/HER2+ disease, and 22% for triple-negative breast cancer (TNBC). HER2-low expression within HR+/HER2− and TNBC subtypes had no impact on brain metastases incidence. Brain metastases prevalence increased per line of therapy for patients with all breast cancer subtypes. Conclusions Brain metastases incidence increases per line of therapy for every MBC subtype. The HER2-low biomarker does not impact brain metastases incidence within historical subtypes.

Year:

2025

Background The phase III RxPONDER trial has affected treatment for node-positive (1-3), hormone receptor-positive, HER2-negative breast cancer with a 21-gene recurrence score (RS) less than 26. We investigated how these findings apply to different racial and ethnic groups within the trial. Methods The trial randomly assigned women to endocrine therapy (ET) or to chemotherapy plus ET. The primary clinical outcome was invasive disease-free survival (IDFS), with distant relapse-free survival (DRFS) as a secondary outcome. Multivariable Cox models were used to evaluate the association between race/ethnicity and survival outcomes, adjusting for clinicopathological characteristics, RS, and treatment. Results A total of 4048 women with self-reported race/ethnicity were included: Hispanic (15.1%), non-Hispanic Black (NHB) (6.1%), Native American/Pacific Islander (0.8%), Asian (8.0%), and non-Hispanic White (NHW) (70%). No differences in RS distribution, tumor size, or number of positive nodes were observed by race/ethnicity. Relative to NHWs, IDFS was worse for NHB participants (5-year IDFS 91.6% vs 87.1%, HR = 1.37; 95% CI = 1.03 to 1.81) and better for Asians (91.6% vs 93.9%, HR = 0.64; 95% CI = 0.46 to 0.91). Relative to NHW, DRFS was worse for NHB participants (5-year DRFS 95.8% vs 91.0%, HR = 1.65; 95% CI = 1.17 to 2.32) and better for Asians (95.8% vs 96.7%, HR = 0.59; 95% CI = 0.37 to 0.95). Adjusting for clinical characteristics, particularly body mass index, diminished the effect of race on outcomes. Chemotherapy treatment efficacy did not differ by race/ethnicity. Conclusions NHB women had worse clinical outcomes compared with NHWs in the RxPONDER trial despite similar RS and comparable treatment. Our study emphasizes the persistent racial disparities in breast cancer outcomes while highlighting complex interactions among contributing factors. Trial Registration ClinicalTrials.gov: NCT01272037.

Year:

2025

Purpose: Cyclin-dependent kinase 4/6 inhibitors can significantly extend survival when given in combination with endocrine therapy in patients with hormone receptor–positive metastatic breast cancer. However, their activity has been relatively underexplored in patients with metastatic triple-negative breast cancer (mTNBC). Patients and Methods: We conducted a single-arm phase II study of abemaciclib monotherapy in patients with Rb-positive mTNBC. Patients were treated with abemaciclib 200 mg orally twice daily until disease progression, unacceptable toxicity, or withdrawal of consent. The primary endpoint was the objective response rate; secondary endpoints included progression-free survival (PFS), overall survival (OS), clinical benefit rate, disease control rate, and safety and tolerability. Results: A total of 27 patients were enrolled before the trial was closed early because of slow accrual. Patients had received a median of two lines of systemic therapy in the metastatic setting prior to enrollment. After a median follow-up of 28.5 months, the objective response rate was 0%, the clinical benefit rate was 14.8%, and the disease control rate was 22.2%. The median PFS was 1.94 months (95% confidence interval, 1.84–11.47), and the median OS was 8.44 months (95% confidence interval, 4.57–15.57). Median PFS and OS did not differ significantly based on androgen receptor and PD-L1 status. Pretreatment gene expression profiling of tumor tissue provided some hypothesis-generating insights into biological features associated with clinical benefit in this study. The most common treatment-related adverse events of grade 2 or higher were diarrhea (40.7%), neutropenia (40.7%), anemia (29.6%), and nausea (29.6%). Conclusions: Abemaciclib monotherapy did not show clinical activity in patients with pretreated Rb-positive mTNBC.

Year:

2025

Supplementary Figure 2 displays the relationship between the week 8 CM level and the change in CM level (Week 8 – baseline). Figure S4B and C use box plots to display the relationship between disease status at first restaging and week 8 CM level or change in CM level (Week 8 – baseline).

Year:

2025

Supplementary figure 5 displays time updated ROC curves for (A) CM level at week 8, (B) Change in CM level (Week8 – Week4) and (C) the Combination of week 8 CM level and Change in CM level (Week 8-Week 4) using linear discriminant analysis.

Year:

2025

PURPOSE Prognostic assessment in hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2–) early breast cancer (EBC) remains challenging, given relatively low rates of disease progression. Modern artificial intelligence (AI)–based techniques have provided advanced prognostic tools in cancer. PATIENTS AND METHODS The Artera multimodal AI (MMAI) platform, using digital histopathology and clinical data, was applied to develop and test a prognostic risk assessment algorithm in HR+/HER2– EBC. Hematoxylin and eosin (H&E) slides from pretreatment breast biopsy and surgical specimens were digitized from the WSG PlanB and ADAPT trials. Patients with available images and complete data (n = 5,259) were stratified by trial, treatment, and distant metastasis (DM) into training (development: 60%) and internal validation (holdout: 40%) cohorts. The algorithm provided prognostic DM risk scores on the basis of image data and clinical variables (age, T and N stages, and tumor size). Univariable and multivariable Fine-Gray models were used to assess performance on the test cohort; subdistribution hazard ratios (sHR) are reported per standard deviation increase of the model scores. Prespecified prognostic subgroups for analysis were defined by nodal status, menopausal status, and tumor grade. RESULTS The trained MMAI score was significantly associated with risk of DM in the test cohort (sHR, 2.3 [95% CI, 2.0 to 2.8]) as a whole and across subgroups. The score remained significant (sHR, 2.2 [95% CI, 1.7 to 2.8]) after adjusting for clinical prognostic factors. The MMAI image component alone had significant prognostic value (sHR, 1.6 [95% CI, 1.3 to 1.9]) in the test cohort; it also had significant prognostic value separately within the G2 and G3 subgroups, with sHR of 1.5 per standard deviation increase, and in most of the other predefined clinical subgroups. CONCLUSION MMAI using digital pathology from H&E slides provides enhanced prognostic quality in HR+/HER2– EBC and could help to advance personalized breast cancer management.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (41)

Alessandro Di Federico

University of Bologna

ITALY
View details

Mark Awad

Chief, Thoracic Oncology Service

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Isabel T Rubio

Clinica Universidad de Navarra

SPAIN
View details

Anne M May

University Medical Center Groningen

NETHERLANDS
View details

Toni Choueiri

Director, Lank Center for Genitourinary Oncology

Dana-Farber Cancer Institute

UNITED STATES
View details

Charles Edward Geyer Jr

Professor of Medicine in Division of Hematology/Medical Oncology

University of Pittsburgh

UNITED STATES
View details

Lisa Anne Carey

Deputy Director for Clinical Science

University of North Carolina at Chapel Hill

UNITED STATES
View details

Chiara Corti

Dana-Farber Cancer Institute

UNITED STATES
View details

Yara G Abdou

University of North Carolina at Chapel Hill

UNITED STATES
View details

Morag Park

McGill University

CANADA
View details

Carey Anders

Assistant Director of Clinical Research

Duke University

UNITED STATES
View details

Julie Gralow

Chief Medical Officer

-

UNITED STATES
View details

Andrew D Cherniack

Group Leader

Dana-Farber Cancer Institute

UNITED STATES
View details

Rita Nanda

Associate Professor of Medicine; Director Breast Oncology

University of Chicago

UNITED STATES
View details

Nadia Harbeck

-

GERMANY
View details

Hope Rugo

Director, Women’s Cancer Program Division; Professor, Department of Medical Oncology & Therapeutics Research; Chief, Breast Medical Oncology

City Of Hope National Medical Center

UNITED STATES
View details

Michael Bates

-

UNITED STATES
View details

Eddy Saad

Dana-Farber Cancer Institute

UNITED STATES
View details

Scott Rodig

Professor of Pathology

Beth Israel Deaconess Medical Center

UNITED STATES
View details

Antonio Giordano

Dana-Farber Cancer Institute

UNITED STATES
View details

Neal Lindeman

Vice Chair, Molecular Pathology and Laboratory Medicine

Weill Cornell Medicine

UNITED STATES
View details

Peter Sorger

Otto Krayer Professor of Systems Pharmacology

Harvard Medical School

UNITED STATES
View details

Glenn Hanna

Dana-Farber Cancer Institute

UNITED STATES
View details

William J. Muller

Professor

McGill University

CANADA
View details

Brittany Bychkovsky

Assistant Professor of Medicine

Dana-Farber Cancer Institute

UNITED STATES
View details

Funda Meric-Bernstam

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Elizabeth Mittendorf

Harvard University

UNITED STATES
View details

Sara Hurvitz

Professor, Division Head

Washington University School of Medicine

UNITED STATES
View details

Antonio Wolff

Professor of Oncology

Johns Hopkins University

UNITED STATES
View details

James Ingle

Mayo Clinic Rochester

UNITED STATES
View details

Lesley Fallowfield

Director, Professor of Psycho-oncology

University of Sussex

UNITED KINGDOM
View details

Sandra M. Swain

Georgetown University Medical Center

UNITED STATES
View details

Sarah Sammons

Assistant Professor

Dana-Farber Cancer Institute

UNITED STATES
View details

Shom Goel

University of Melbourne

AUSTRALIA
View details

Priya Kumthekar

Northwestern Medicine

UNITED STATES
View details

Kala Visvanathan

Professor

Johns Hopkins University

UNITED STATES
View details

Michel L. Tremblay

James McGill Distinguished Professor

McGill University

CANADA
View details

Erica Mayer

Dana-Farber Cancer Institute

UNITED STATES
View details

Filipa Lynce

Dana-Farber Cancer Institute

UNITED STATES
View details

Eric Winer

Director

Yale University

UNITED STATES
View details

Saraswati Sukumar

Professor

Johns Hopkins University School of Medicine

UNITED STATES
View details